Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ.

Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14.

2.

Recent progress in gene therapy for Parkinson's disease.

Nakata Y, Yasuda T, Mochizuki H.

Curr Mol Med. 2012 Dec;12(10):1311-8. Review.

PMID:
22834832
3.

[Gene therapy using AAV].

Ozawa K.

Uirusu. 2007 Jun;57(1):47-55. Review. Japanese.

4.

Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.

Ozawa K, Fan DS, Shen Y, Muramatsu S, Fujimoto K, Ikeguchi K, Ogawa M, Urabe M, Kume A, Nakano I.

J Neural Transm Suppl. 2000;(58):181-91. Review.

PMID:
11128607
5.

[AAV vector-mediated gene transfer and its application to the nervous system].

Ozawa K.

Rinsho Shinkeigaku. 2003 Nov;43(11):835-8. Review. Japanese.

PMID:
15152479
6.

AADC deficiency: occurring in humans, modeled in rodents.

Hwu WL, Lee NC, Chien YH, Muramatsu S, Ichinose H.

Adv Pharmacol. 2013;68:273-84. doi: 10.1016/B978-0-12-411512-5.00013-0. Review.

PMID:
24054149
7.

[Gene therapy for Parkinson's disease].

Muramatsu S.

Brain Nerve. 2007 Apr;59(4):425-30. Review. Japanese.

PMID:
17447529
8.

[Gene therapy for Parkinson's disease: studies in animal models].

Muramatsu S.

Rinsho Shinkeigaku. 2001 Dec;41(12):1157-9. Review. Japanese.

PMID:
12235825
9.

The current status of gene therapy for Parkinson's disease.

Muramatsu S.

Ann Neurosci. 2010 Apr;17(2):92-5. doi: 10.5214/ans.0972-7531.1017209. Review.

Supplemental Content

Support Center